List view / Grid view
In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust supply of high-quality, fit-for-purpose consumables is critical.
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Learn practical tips from eight Principal Investigators about how to start your own lab.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
7 May 2020 | By PerkinElmer
High-throughput screening (HTS) cascades have evolved to ensure that high quality hits can be identified from large screening collections.
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
